Compare GSK plc (GSK) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs S&P Global Inc — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while S&P Global Inc trades at $454.5 (market cap $131.57B). The key difference: S&P Global Inc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | SPGI | |
|---|---|---|
Market Cap | $101.34B | $131.57B |
Sector | Health | Financials |
52-Week High | $61.18 | $534.79 |
52-Week Low | $36.20 | $370.42 |
Enterprise Value | $121.95B | $143.53B |
Dividend Yield | 3.49% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
S&P Global (SPGI) trades at $454.50, up 3.56% today, with a bullish technical outlook and strong analyst consensus. Recent Q1 2026 earnings beat expectations, and the company maintains robust profitability with a 30.36% net margin. The recent spin-off of Mobility Global streamlines operations, while new AI-driven offerings in Market Intelligence signal growth potential. Cash flow remains positive, supporting dividend payments and strategic investments.
The outlook is positive, driven by margin expansion targets and resilient recurring revenues. Risks include elevated valuation multiples and sensitivity to debt issuance cycles. With 86% analyst buy ratings and a $532.38 price target, Wall Street sees upside, but investors should monitor execution on AI integration and competitive pressures in data services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
